Study to Evaluate D-1553 in Subjects With Lung Cancer
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors
Sponsor: InventisBio Co., Ltd
Listed as NCT05383898, this PHASE1/PHASE2 trial focuses on NSCLC and remains completed. Sponsored by InventisBio Co., Ltd, it has been updated 6 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Nov 2024 — Present [monthly]
Completed PHASE1/PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Nov 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 1 earlier version
-
Jun 2022 — Nov 2023 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- InventisBio Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .